Abstract
Prostate cancer (PC) has become a disease that poses a serious threat to men's health and life. In recent years, due to changes in environment, lifestyle, and other factors, the incidence of PC has been increasing rapidly. Ent-Dihydrotucumanoic Acid (DTA) is a compound isolated from the Asteraceae family of gymnosperms, known for various pharmacological effects. This study investigated the effect of DTA on the growth of the PC-3 human prostate cancer cell line using CCK-8 assays, flow cytometry for mitochondrial membrane potential and apoptosis, Western blot for apoptosis-related genes, and spectrophotometry for Caspase-3 and Caspase-9 activity. The findings indicate that DTA induces apoptosis in PC-3 cells through the mitochondrial pathway, laying an experimental foundation for the further development of DTA as a therapeutic agent.
Introduction
Prostate cancer remains a leading cause of mortality among men globally. While early-stage PC is often treatable, late-stage cases frequently progress to steroid-resistant forms that are difficult to manage with current chemotherapies, which often carry significant side effects. This study investigates the anti-cancer potential of Ent-Dihydrotucumanoic acid (DTA), a natural compound derived from the Asteraceae family. Researchers aimed to determine if DTA could selectively induce apoptosis in malignant PC-3 cells by disrupting their internal signaling pathways.
Methods
The study utilized the PC-3 human prostate cancer cell line. Key assays included:
- CCK-8 Assay: To measure cell viability across various DTA concentrations (0–40 μM) and time points (24–72 hours).
- Flow Cytometry: To quantify apoptosis rates (Annexin V-PE/7-AAD) and Mitochondrial Membrane Potential (Δψm) using Rhodamine 123 staining.
- Western Blotting: To analyze expression levels of regulatory proteins: Bcl-2 (anti-apoptotic), Bax (pro-apoptotic), and Cytochrome C.
- Colorimetric Assays: To measure the activation levels of Caspase-3 and Caspase-9, the "executioner" enzymes of apoptosis.
Key Results: Growth Inhibition
DTA significantly inhibited PC-3 cell proliferation in both a time- and dose-dependent manner. As DTA concentration increased, cell viability markedly decreased across the 72-hour observation period.
At the highest concentration tested (40 μM), the apoptosis rate reached over 80%, compared to approximately 10% in the control group, indicating a potent "suicide" switch triggered by the compound.
Mechanism: The Mitochondrial Pathway
The study revealed that DTA triggers the intrinsic apoptotic pathway by disrupting the mitochondrial "rheostat." Specifically, DTA treatment led to a significant decrease in the anti-apoptotic protein Bcl-2 and a concurrent increase in the pro-apoptotic protein Bax.
This shift in the Bax/Bcl-2 ratio facilitates the leakage of Cytochrome C from the mitochondria into the cytoplasm (Cyto-CytC)—a critical "point of no return" for cell death. This leakage subsequently activates the Caspase cascade (Caspase-9 and Caspase-3), leading to the systematic dismantling of the cancer cell.
Conclusion and Future Directions
While DTA shows strong potential as a natural-product-based therapy for prostate cancer, several hurdles remain. This in vitro study provides a foundational mechanical explanation but lacks in vivo validation. Future research must establish the compound's safety profile in healthy tissues, determine its bioavailability, and test its efficacy in animal models to confirm if these cellular effects translate to tumor reduction in a living system.
Summary updated